Courtney B Munro

Dr. Courtney B Munro

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2023 in Journal of Pediatric and Adolescent Gynecology
Verified
Journal Article
Open access
CMCourtney B Munro
Courtney B Munro
EWEmma N. Walker
Emma N. Walker
RSRachel Schembri
Rachel Schembri
DMDehlia Moussaoui
Dehlia Moussaoui
SGSonia Grover
Sonia Grover
Few studies have explored what specific outcome measures contained in assessment tools for period and pelvic pain are most relevant to adolescents. Co-design is a valuable method of ensuring input from those with lived experience. The Longitudinal Study of Teenagers with Endometriosis Periods and Pelvic Pain in Australia (LongSTEPPP) Co-Design Periods Survey comprised an anonymous online survey of adolescents' experience of menstruation to inform patient-reported outcome measures for the larger 5-year project. Adolescents aged 12-18 years whose periods had commenced at least 3 months previously and with demonstrated capacity to consent were invited to participate in an online survey. Recruitment was primarily via social media channels. Of the 1811 adolescents who participated, 85% reported that periods had a "moderate" or greater impact on their life. Pain (90.7%), heavy flow (56.2%), and worry about leakage (49%) were common reasons for missed activities. Menstrual symptoms were wide-ranging and included cramping, nausea, poor energy, and impacts on mood. When asked where adolescents sought assistance with their periods, 39.8% had seen their general practitioner, 21.3% their school nurse, and almost 1 in 10 had consulted a mental health practitioner (9.3%). To manage menstrual symptoms, heat packs (66.0%), over-the-counter medications (55.8%), and prescription medications (28.6%) were used. We found a lack of menstrual health awareness in adolescents. Periods had a significant effect on their lives, and adolescents commonly missed activities. In managing menstruation, a wide range of practitioners were consulted. Nearly a third were prescribed medication to manage their periods. These findings have directed the longitudinal study as to how best to capture outcome measures that reflect the impact of periods on adolescents.

18 December 2019 in Journal of Pharmacy Practice and Research
Verified
Journal Article
Closed access
PDF file
SWSusan Welch
Susan Welch
ECElizabeth Currey
Elizabeth Currey
EDElizabeth Doran
Elizabeth Doran
AHAndrew Harding
Andrew Harding
CRCristina Roman
Cristina Roman
CMCourtney B Munro
Courtney B Munro

20 December 2020 in Journal of Pharmacy Practice and Research
Verified
Journal Article
Closed access
PDF file
JCJohn Coutsouvelis
John Coutsouvelis
JAJulie Adams
Julie Adams
HBHadley Bortz
Hadley Bortz
MCMaggie Chau
Maggie Chau
KCKaren Chiang
Karen Chiang
CMCourtney B Munro
Courtney B Munro

29 April 2021 in Journal of Pharmacy Practice and Research
Verified
Journal Article
Closed access
PDF file
KJKarlee Johnston
Karlee Johnston
MAMelissa J. Ankravs
Melissa J. Ankravs
BBBelinda Badman
Belinda Badman
CCChui Lynn Choo
Chui Lynn Choo
MCMichele Cree
Michele Cree
CMCourtney B Munro
Courtney B Munro

16 February 2020 in Journal of Pharmacy Practice and Research
Verified
Journal Article
Closed access
PDF file
Rohan A ElliottRohan A Elliott
Rohan A Elliott
ACAlex Chan
Alex Chan
GGGauri Godbole
Gauri Godbole
IHIvanka Hendrix
Ivanka Hendrix
LPLisa G. Pont
Lisa G. Pont
CMCourtney B Munro
Courtney B Munro

7 August 2025 in Life
Verified
Journal Article
Open access
PDF file
TTTheeba Thiruchelvam
Theeba Thiruchelvam
CLChiao Xin Lim
Chiao Xin Lim
CMCourtney B Munro
Courtney B Munro
VCVincent Chan
Vincent Chan
GJGeshani Jayasuria
Geshani Jayasuria
VSVijay Suppiah
Vijay Suppiah
People with cystic fibrosis may experience polypharmacy, which can increase the risk of drug induced complications such as adverse events and drug–drug interactions. This study aimed to examine the prevalence of adverse events and to identify potential drug–drug interactions associated with elexacaftor/tezacaftor/ivacaftor (ETI). Three databases, the Australian Therapeutic Goods Administration Database of Adverse Event Notification (TGA DAEN), the Canada Vigilance Adverse Reaction Online Database (CVAROD), and the USA Food and Drug Administration Adverse Event Reporting System (FAERS) Database were searched for spontaneous ETI adverse events between 2019 and 2024. Descriptive analysis of the data was undertaken. The FAERS database was analysed to identify adverse events of interest such as anxiety and depression and concomitant drugs prescribed with ETI. A total of 10,628 ETI associated adverse events were identified in all system organ classes. The incidence of psychiatric adverse events ranged from 7 to 15% across the three databases. Potential drug–drug interactions with CYP 3A4/5 strong inhibitors and strong inducers were identified from the FAERS database and azole antifungals were implicated in several ETI dose modifications. The prevalence and types of ETI adverse events were varied and use of concomitant drugs with potential drug interactions was significant, requiring more research to manage them.